Ipsen announces positive results from phase III CLARINET study of Somatuline Autogel

15-Jul-2013 - France

Ipsen  announced results from the primary endpoint of the CLARINET study, assessing the effect of Somatuline® Autogel® 120 mg on tumor progression-free survival in patients with GEP-NETs. Treatment with Somatuline® Autogel® 120mg was found to be statistically significantly superior to placebo in extending time to either disease progression or death. The safety profile observed in the study is consistent with the known safety profile of Somatuline®

Pr Martyn Caplin, Professor of Gastroenterology & Gastrointestinal Neuroendocrinology, Royal Free Hospital (London, UK) and Principal Investigator of CLARINET, commented: “CLARINET is the first prospective large scale placebo-controlled study inclusive of gastrointestinal and pancreatic NETs which provides clear evidence that Somatuline® Autogel® 120mg delays tumor progression or death. These important results will help the medical community to confirm the place of Somatuline® Autogel® in the treatment algorithm of these patients.”

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...